|Positive WB detected in||RAW 264.7 cells, A2780 cells|
|Positive IP detected in||RAW 264.7 cells|
|Positive FC detected in||U-937 cells|
|Western Blot (WB)||WB : 1:500-1:1000|
|Immunoprecipitation (IP)||IP : 0.5-4.0 ug for IP and 1:200-1:1000 for WB|
|Sample-dependent, check data in validation data gallery|
The immunogen of 10286-1-AP is uPAR Fusion Protein expressed in E. coli.
|Tested Reactivity||human, mouse|
|Cited Reactivity||human, mouse|
|Host / Isotype||Rabbit / IgG|
|Immunogen||uPAR fusion protein Ag0187|
|Calculated molecular weight||37 kDa|
|Observed molecular weight||35-70 kDa|
|GenBank accession number||BC002788|
|Gene ID (NCBI)||5329|
|Purification Method||Antigen affinity purification|
|Storage Buffer||PBS with 0.02% sodium azide and 50% glycerol pH 7.3.|
|Storage Conditions||Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.|
uPAR is a 45-65 kDa, highly glycosylated, GPI-anchored membrane protein. In addition to the membrane-anchored form, uPAR is released from the plasma membrane by cleavage of the GPI anchor and can be found as a soluble form (suPAR). uPAR contains three homologous domains (D1-D3) of which the N-terminal one (D1) represents the uPA-binding domain. After binding to uPAR, uPA cleaves plasminogen, generating the active protease plasmin which is involved in a wide variety of physiologic and pathologic processes. In addition to regulating proteolysis, uPAR has important function in cell adhesion, migration and proliferation. Studies reveal that uPAR expression is elevated during inflammation and tissue remodelling and in many human cancers, in which it frequently indicates poor prognosis. (PMID 20027185; 12461559)
Cancer Cell Int
Identification of an immune-related signature indicating the dedifferentiation of thyroid cells.
Ulinastatin Inhibits Osteoclastogenesis and Suppresses Ovariectomy-Induced Bone Loss by Downregulating uPAR.
Forkhead Box Q1 Is Critical to Angiogenesis and Macrophage Recruitment of Colorectal Cancer.
J Inflamm Res
PLAUR as a Potential Biomarker Associated with Immune Infiltration in Bladder Urothelial Carcinoma.